Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.
We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.
91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).
We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.
European journal of cancer (Oxford, England : 1990). 2017 May 23 [Epub ahead of print]
Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, Grant D Stewart, Kate Fife, James Larkin, Andrea Biondo, Lisa Pickering, Anandagopal Srinivasan, Helen Boyle, Lisa Derosa, Cora N Sternberg, Federica Recine, Christy Ralph, Carolina Saldana, Philippe Barthélémy, Jean Christophe Bernhard, Howard Gurney, Gregory Verhoest, Elodie Vauleon, Pierre Bigot, Julien Berger, Christian Pfister, Gwenaelle Gravis, Jean-Michel Rodier, Stéphane Culine, Armelle Caty, Frederic Rolland, Franck Priou, Bernard Escudier, Laurence Albiges
Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France., Department of Biostatistics and Epidemiology, Gustave Roussy, INSERM U1018, CESP, Université Paris-Saclay, Villejuif, F-94805, France., Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK; Academic Urology Group, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK., Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Medical Oncology, The Royal Marsden Hospital, Fulham Road, London, UK., Medical Oncology, Centre Léon Bérard, Lyon, France., Medical Oncology, Istituto Toscano Tumori, Pisa, Italy., Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy., Department of Medical Oncology, Institute of Cancer Studies & Pathology University of Leeds, Leeds, UK., Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France., Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Department of Urology, CHU de Bordeaux, Bordeaux, France., Faculty of Medicine and Health Sciences Macquarie University, Sydney, Australia., Department of Urology, CHU de Rennes, Rennes, France., Medical Oncology, Centre Eugène Marquis, Rennes, France., Medical Oncology, CHU d'Angers Angers, France., Department of Urology, CHU Dupuytren, Limoges, France., Department of Urology, CHU Charles Nicolle, Rouen, France., Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Medical Oncology, Hôpital Bichat Paris, France., Medical Oncology, Hôpital Saint Louis Paris, France., Medical Oncology, Hopital privée la Louvière Lille, France; Medical Oncology, Centre Oscar Lambret Lille, France., Medical Oncology, Institut René Gauducheau Saint Herblain, France., Medical Oncology, Centre Hospitalier de Vendée La Roche sur Yon, France., Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France. Electronic address: .